GLEN ALLEN, Va., Feb. 14, 2014 /PRNewswire/ -- Star Scientific, Inc., (NASDAQ: STSI) today announced that the Company will host an Analyst and Investor meeting for research analysts, and institutional and other investors, on Thursday, March 20, 2014, from 1:00 PM (EDT) to 3:00 PM in Sarasota, Florida, at the Roskamp Institute. Michael Mullan, M.D.(MBBS), Ph.D., Chairman and Chief Executive Officer of Star Scientific, along with Chris Chapman, M.D., President, will lead the Company's presentations. The presentations will focus on the scientific foundations of the Company's technology, the progress of its research and development programs, and the Company's near-term and long-term pharmaceutical strategy.
(Logo: http://photos.prnewswire.com/prnh/20130319/PH79245LOGO )
A live video webcast of the Analyst and Investor meeting will be accessible to the public through the Investor Relations section of Star Scientific's website at: http://www.starscientific.com/investors. Instructions relating to the electronic submission of questions from the webcast audience will be provided on the Company website as the meeting date approaches.
Registration is required to attend the meeting in Sarasota and seating is limited. Individuals interested in attending the meeting in person will be able to register, beginning February 19, 2014, through a link on the Company's website (www.starscientific.com).
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical dietary supplements products, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices and the outcome of the ongoing investigations as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2012 and our quarterly reports on Form 10-Q for the quarters ended March 31, 2013, June 30, 2013, and September 30, 2013. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
About Star Scientific
Star Scientific, Inc. is a technology-oriented company with a mission to promote maintenance of a healthy metabolism and lifestyle. Through its wholly owned subsidiary, Rock Creek Pharmaceuticals, Star Scientific has been engaged in the manufacturing, sale, and marketing of two nutraceutical dietary supplements, a cosmetic facial cream, a facial serum, and the development of other nutraceuticals and pharmaceuticals. The company also continues to pursue the licensing of the technology behind its proprietary StarCured® curing process and its related products.
CONTACT:
Talhia T. Tuck
Vice President, Communications and Investor Relations
Star Scientific, Inc.
(202) 887-5100
ttuck@starscientific.com
Ted Jenkins
Vice President, Corporate Strategy and Development
Rock Creek Pharmaceuticals
tjenkins@rockcreekpharmaceuticals.com
SOURCE Star Scientific, Inc.